Results 161 to 170 of about 3,946 (192)
Some of the next articles are maybe not open access.
Nephron, 2023
Renal transplant recipients are at increased risk for the development of a malignant neoplasm. Polyomavirus-associated urothelial carcinoma is a rare tumor that occurs in renal transplant recipients, with approximately 41 cases reported since 2002. It accounts for 27–31% of all post-transplant urothelial carcinomas and develops at an average of 8.5 ...
Sari Iwasaki +9 more
openaire +2 more sources
Renal transplant recipients are at increased risk for the development of a malignant neoplasm. Polyomavirus-associated urothelial carcinoma is a rare tumor that occurs in renal transplant recipients, with approximately 41 cases reported since 2002. It accounts for 27–31% of all post-transplant urothelial carcinomas and develops at an average of 8.5 ...
Sari Iwasaki +9 more
openaire +2 more sources
Granulomatous inflammation in
AbstractEvolving BK polyomavirus–associated nephropathy (BKPyVAN) is characterized by tubulointerstitial inflammation that closely resembles acute T‐cell–mediated allograft rejection if tubulitis is significant. The cellular composition of the inflammation varies during the course of BKPyVAN, and clusters of plasma cells may herald resolution of the ...
Yang Zhang +5 more
openaire +2 more sources
Ultrasound findings of BK polyomavirus-associated nephropathy in renal transplant patients
Journal of Nephrology, 2016BK polyomavirus (BKV) is an emerging pathogen in immunocompromised patients. BKV infection occurs in 1-9 % of renal transplants and causes chronic nephropathy or graft loss. Diagnosis of BKV-associated nephropathy (BKVAN) is based on detection of viruria then viremia and at least a tubule-interstitial nephritis at renal biopsy. This paper describes the
Mauro Dugo +11 more
openaire +3 more sources
Transplantation Reviews, 2020
BK polyomavirus (BKPyV) associated nephropathy (BKVAN) is seen in about 5% of renal transplant patients and can lead to chronic graft failure or graft loss. No effective therapy is available. Leflunomide has shown promising results in BKVAN. We performed a systematic review about the use of leflunomide for the treatment of BKVAN. The recommendations of
Laila, Schneidewind +4 more
openaire +2 more sources
BK polyomavirus (BKPyV) associated nephropathy (BKVAN) is seen in about 5% of renal transplant patients and can lead to chronic graft failure or graft loss. No effective therapy is available. Leflunomide has shown promising results in BKVAN. We performed a systematic review about the use of leflunomide for the treatment of BKVAN. The recommendations of
Laila, Schneidewind +4 more
openaire +2 more sources
BK Polyomavirus‐associated nephropathy managed by screening policy in a real‐life setting
Transplant Infectious Disease, 2019AbstractBackgroundBK polyomavirus‐associated nephropathy (PyVAN) is an important complication after kidney transplantation. Prevalence ranges from 1% to 10%, and graft loss occurs in approximately 50% of the cases. There is no effective treatment, so early viral detection with immunosuppression tapering is the current strategy to prevent PyVAN.AimsTo ...
Fernanda Vianna Vacilotto Raupp +8 more
openaire +2 more sources
BK virus infection activates the TNFα/TNF receptor system in Polyomavirus-associated nephropathy
Molecular and Cellular Biochemistry, 2015Polyomavirus-associated nephropathy due to BK virus infection (BKVAN) is recognized as an important cause of significant kidney transplant dysfunction often leading to renal graft loss. The activation of innate immune defense mechanisms during BKVAN is still poorly understood and an altered regulation of inflammatory mediators by resident kidney cells ...
Andrea, Ribeiro +5 more
openaire +2 more sources
Transplant Infectious Disease, 2016
AbstractA 58‐year‐old renal transplant recipient underwent biopsy 11 weeks post transplantation for increasing creatinine. The biopsy showed cytomegalovirus (CMV) glomerulitis together with BK polyomavirus (BKPyV)‐associated nephropathy (PVAN). Treatment with intravenous ganciclovir and overall reduction in maintenance immunosuppression resulted in ...
I O, Chikeka +4 more
openaire +2 more sources
AbstractA 58‐year‐old renal transplant recipient underwent biopsy 11 weeks post transplantation for increasing creatinine. The biopsy showed cytomegalovirus (CMV) glomerulitis together with BK polyomavirus (BKPyV)‐associated nephropathy (PVAN). Treatment with intravenous ganciclovir and overall reduction in maintenance immunosuppression resulted in ...
I O, Chikeka +4 more
openaire +2 more sources
Transplant Infectious Disease, 2019
AbstractBackgroundBK polyomavirus associated nephropathy (BKPyVAN) is a significant clinical issue in kidney transplant (KT) recipients. No specific therapy is currently available, although treatment with leflunomide may be part of the therapeutic strategy. Here, we sought to examine the impact of leflunomide on the evolution of BKPyVAN.MethodsThis was
Nicolas Keller +2 more
exaly +3 more sources
AbstractBackgroundBK polyomavirus associated nephropathy (BKPyVAN) is a significant clinical issue in kidney transplant (KT) recipients. No specific therapy is currently available, although treatment with leflunomide may be part of the therapeutic strategy. Here, we sought to examine the impact of leflunomide on the evolution of BKPyVAN.MethodsThis was
Nicolas Keller +2 more
exaly +3 more sources
Transplantation Proceedings, 2010
BK polyomavirus-associated nephropathy (BKPVAN) is a major cause of renal failure early after kidney transplantation. The present study reports the preliminary results of prospective monitoring including a preemptive strategy for BKPVAN during the first year after kidney transplantation.We monitored BK virus DNA in blood at months 1, 2, 3, 6, 9, and 12
E, Renoult +11 more
openaire +2 more sources
BK polyomavirus-associated nephropathy (BKPVAN) is a major cause of renal failure early after kidney transplantation. The present study reports the preliminary results of prospective monitoring including a preemptive strategy for BKPVAN during the first year after kidney transplantation.We monitored BK virus DNA in blood at months 1, 2, 3, 6, 9, and 12
E, Renoult +11 more
openaire +2 more sources
Transplantation Proceedings, 2019
Graft biopsy is the gold standard for diagnosis of BK polyomavirus-associated nephropathy (BKPyVAN), and polymerase chain reaction is the most specific screening technique. Development of a noninvasive, cost-effective marker for BKPyVAN is important.We reviewed 492 adult kidney transplant patients.
Kosuke, Masutani +12 more
openaire +2 more sources
Graft biopsy is the gold standard for diagnosis of BK polyomavirus-associated nephropathy (BKPyVAN), and polymerase chain reaction is the most specific screening technique. Development of a noninvasive, cost-effective marker for BKPyVAN is important.We reviewed 492 adult kidney transplant patients.
Kosuke, Masutani +12 more
openaire +2 more sources